The First Clinical Medical College, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Department of Gastrointestinal Surgery, Xuzhou Cancer Hospital, Xuzhou, 221005, Jiangsu, China.
World J Surg Oncol. 2022 Mar 20;20(1):89. doi: 10.1186/s12957-022-02557-7.
Colon adenocarcinoma (COAD) is one of the common cancers worldwide. Collagen triple helix repeat containing 1 (CTHRC1) has been reported to be involved in cell invasion, angiogenesis, and the promotion of epithelial-mesenchymal transformation by mediating multiple signaling pathways. However, the role of CTHRC1 in COAD has not yet been determined.
Differentially expressed genes were evaluated using gene expression data from the Oncomine and TIMER databases. Correlations between CTHRC1 gene expression and clinicopathological factors were analyzed using gene expression data from UALCAN databases. Then, we searched the GEPIA database to evaluate the association of CTHRC1 gene expression with clinical outcomes. The cBioPortal database was used to analyze CTHRC1 genetic alterations. Subsequently, the TIMER website was chosen to assess the correlation of CTHRC1 with the tumor immune cell infiltration level. The TCGA dataset was used for a gene set enrichment analysis (GSEA).
CTHRC1 was highly expressed in COAD patients, and significantly related to poor prognosis. In addition, elevated expression of CTHRC1 was related to the clinical stage and pathological type of COAD. The GSEA analysis showed that CTHRC1 was enriched in Gα signaling, GCPR ligand binding, neutrophil degranulation, interleukin signaling, and tumor-associated pathways. In addition, CTHRC1 was significantly associated with the expression of multiple immune markers related to specific immune cells.
This study suggest that CTHRC1 expression is related to the prognosis and immune infiltration of COAD patients. Therefore, CTHRC1 may be a new candidate prognostic biomarker for determining immune infiltration levels and providing COAD prognoses.
结肠腺癌（COAD）是全球常见的癌症之一。胶原三螺旋重复包含 1 型（CTHRC1）已被报道通过介导多种信号通路参与细胞侵袭、血管生成和上皮-间充质转化的促进。然而，CTHRC1 在 COAD 中的作用尚未确定。
使用 Oncomine 和 TIMER 数据库中的基因表达数据评估差异表达基因。使用 UALCAN 数据库中的基因表达数据分析 CTHRC1 基因表达与临床病理因素的相关性。然后，我们在 GEPIA 数据库中搜索评估 CTHRC1 基因表达与临床结局的关联。使用 cBioPortal 数据库分析 CTHRC1 遗传改变。随后，选择 TIMER 网站评估 CTHRC1 与肿瘤免疫细胞浸润水平的相关性。使用 TCGA 数据集进行基因集富集分析（GSEA）。
CTHRC1 在 COAD 患者中高表达，与预后不良显著相关。此外，CTHRC1 的高表达与 COAD 的临床分期和病理类型有关。GSEA 分析表明，CTHRC1 富集在 Gα 信号、GCPR 配体结合、嗜中性粒细胞脱颗粒、白细胞介素信号和肿瘤相关途径中。此外，CTHRC1 与与特定免疫细胞相关的多种免疫标志物的表达显著相关。
本研究表明，CTHRC1 的表达与 COAD 患者的预后和免疫浸润有关。因此，CTHRC1 可能是一种新的候选预后生物标志物，用于确定免疫浸润水平并提供 COAD 预后。
